公开(公告)号：US20090269363A1

公开(公告)日：2009-10-29

申请号：US12186856

申请日：2008-08-06

申请人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  David Alexandre Gross

发明人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  David Alexandre Gross

IPC分类号： A61K39/00 ,  G01N33/567 ,  A61K38/00 ,  C07H21/02 ,  A61K31/7088 ,  A61P37/04

CPC分类号： C07K14/005 ,  C07K14/71 ,  C12N9/1241 ,  C12N2740/16222 ,  G01N33/56977

摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).

摘要翻译： 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位， 来自提高细胞毒性T细胞（CTL）应答的蛋白质。 （II）对应于对I类分子具有低亲和力的非免疫原性肽。 制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。 然后鉴定衍生活性（IIa）的肽序列。 还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa） 和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

公开(公告)号：US09868770B2

公开(公告)日：2018-01-16

申请号：US13109491

申请日：2011-05-17

申请人： Véronique Bordas ,  Laetitia Bussieres ,  Sabi Airouche ,  Sophie Tourdot ,  Emmanuel Nony ,  Philippe Moingeon ,  Julien Bouley

发明人： Véronique Bordas ,  Laetitia Bussieres ,  Sabi Airouche ,  Sophie Tourdot ,  Emmanuel Nony ,  Philippe Moingeon ,  Julien Bouley

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N1/00 ,  C12N1/20 ,  C12N15/00 ,  C12N15/09 ,  C12P21/04 ,  C12P21/06 ,  C07K14/435 ,  C12N1/16 ,  C12P21/00

CPC分类号： C07K14/43531 ,  C07H21/02 ,  C07H21/04 ,  C12N1/00 ,  C12N1/16 ,  C12N1/20 ,  C12N15/00 ,  C12N15/09 ,  C12P21/00

摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.

公开(公告)号：US20110293665A1

公开(公告)日：2011-12-01

申请号：US13109491

申请日：2011-05-17

申请人： Véronique BORDAS ,  Laetitia Bussieres ,  Sabi Airouche ,  Sophie Tourdot ,  Emmanuel Nony ,  Philippe Moingeon ,  Julien Bouley

发明人： Véronique BORDAS ,  Laetitia Bussieres ,  Sabi Airouche ,  Sophie Tourdot ,  Emmanuel Nony ,  Philippe Moingeon ,  Julien Bouley

IPC分类号： A61K39/35 ,  C12P21/00 ,  C07K14/435

CPC分类号： C07K14/43531 ,  C07H21/02 ,  C07H21/04 ,  C12N1/00 ,  C12N1/16 ,  C12N1/20 ,  C12N15/00 ,  C12N15/09 ,  C12P21/00

摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.

摘要翻译： 本发明涉及一种生产重组体Dermatophagoides pteronyssinus 2蛋白（rDer p2）的方法，包括以下步骤：培养先前用rDer p2编码序列转化的巴斯德毕赤酵母菌株，并从所述毕赤酵母中分离rDer p2蛋白 巴斯德毕赤酵母菌株。 本发明还涉及包含用于治疗或诊断用途的rDer p2蛋白的组合物和试剂盒。

公开(公告)号：US07976843B2

公开(公告)日：2011-07-12

申请号：US12186856

申请日：2008-08-06

申请人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  David Alexandre Gross

发明人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  David Alexandre Gross

IPC分类号： A61K39/00 ,  C07K2/00

CPC分类号： C07K14/005 ,  C07K14/71 ,  C12N9/1241 ,  C12N2740/16222 ,  G01N33/56977

摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).

摘要翻译： 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位， 来自提高细胞毒性T细胞（CTL）应答的蛋白质。 （II）对应于对I类分子具有低亲和力的非免疫原性肽。 制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。 然后鉴定衍生活性（IIa）的肽序列。 还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa） 和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

公开(公告)号：US07425606B2

公开(公告)日：2008-09-16

申请号：US10333430

申请日：2001-07-20

申请人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  Alexandre David Gross

发明人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  Alexandre David Gross

IPC分类号： C07K2/00

CPC分类号： C07K14/005 ,  C07K14/71 ,  C12N9/1241 ,  C12N2740/16222 ,  G01N33/56977

摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).

摘要翻译： 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位， 来自提高细胞毒性T细胞（CTL）应答的蛋白质。 （II）对应于对I类分子具有低亲和力的非免疫原性肽。 制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。 然后鉴定衍生活性（IIa）的肽序列。 还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa） 和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。